Physician profile
Robin Taul
NPI 1508631029
$1,432.58
in general payments reported to CMS, 2019-2025
11 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Psychiatric/Mental Health, Geropsychiatric provider received nationally (typical 2025 total: $510).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $77.75 · 2024: $509 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,432.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $493.45 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $240.68 | 2024-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $191.96 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $164.72 | 2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $91.43 | 2024-2025 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $69.68 | 2024-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $61.00 | 2024 | Invega Trinza, Invega Sustenna |
| Tris Pharma INC | $46.70 | 2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.72 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $18.73 | 2025 | Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $13.51 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Taul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.